JY-231
- Generic Name
- JY-231
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaB-Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Affiliated Hospital of Guangdong Medical University
- Target Recruit Count
- 20
- Registration Number
- NCT06940960
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- He Huang
- Target Recruit Count
- 24
- Registration Number
- NCT06902025
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- He Huang
- Target Recruit Count
- 45
- Registration Number
- NCT06887985
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaB-Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Shenzhen Genocury Biotech Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06890065
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- He Huang
- Target Recruit Count
- 24
- Registration Number
- NCT06879470
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
- Conditions
- Autoimmune Diseases of the Nervous System
- Interventions
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06797024
- Locations
- 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06689917
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China, Wuhan, Hubei, China
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Shenzhen Genocury Biotech Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06678282
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhenzhou, Henan, China
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- Target Recruit Count
- 20
- Registration Number
- NCT06675422
- Locations
- 🇨🇳
920th HJointLogistics, Kunming, Yunnan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.